bioRxivBiophysicsPreprint
Biophysical and Colloidal Properties Govern Anti-Drug Antibody Generation: A Case Study Using the Tumoricidal mAb 4713
Sanjida Yesmin, Mohammad Monirul Islam, Md. Din IslamiD, Hiromichi Tsurui, Tomonori SaotomeiD, Shuji MatsuokaiD, Yutaka KurodaiD
Abstract
Anti-drug antibodies (ADA) are a well-recognized clinical problem, but their sporadic occurrence has limited detailed biophysical characterization of causative factors. We investigated how different stress conditions influence aggregation of a murine monoclonal antibody, mAb 4713, and the resulting potential to induce ADA in mice. Dynamic light scattering (DLS) revealed that stirring, freeze-thaw, and heat stress each generated subvisible aggregates (30-700 nm), whereas non-stressed mAb 4713 remained predominantly monomeric. Stirring- and freeze-thaw-induced aggregates retained native-like secondary and tertiary structures, thermal and biochemical stability, and anti-tumor cytotoxicity, as shown by circular dichroism, tryptophan fluorescence, thermal shift assay, limited proteolysis, and cell death assay. In contrast, heat-induced aggregates displayed complete structural denaturation and loss of cytotoxic activity. Immunization of Jcl: ICR mice demonstrated that heat-induced aggregates were only mildly immunogenic, while freeze-thawed and non-stressed mAb 4713 elicited no detectable immune response, and ADA generated under these conditions did not affect anti-tumor activity. Strikingly, stirred aggregates triggered a strong anti-mAb antibody response, as measured by ELISA, and the resulting antisera completely abolished mAb 4713 cytotoxicity against Raji cells, a Burkitt lymphoma cell line, indicating induction of neutralizing ADA. These results show that aggregate immunogenicity depends not simply on aggregate presence but critically on their structural and colloidal properties and formation pathways, highlighting the need to assess both structural and colloidal properties of aggregates in biopharmaceutical development to mitigate ADA risks.
- organism: mouse
- assay: protein structure
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment with TNF-alpha Antagonists
A. Vaisman-Mentesh, S. Rosenstein, … Y. Wine·bioRxiv·Dec 11, 2019
- Stable High-Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer Excipient
J. H. Klich, C. M. Kasse, … E. Appel·bioRxiv·May 25, 2022
- Cell targeting and immunostimulatory properties of a novel Fcγ-receptor independent agonistic anti-CD40 antibody in rhesus macaques
- Dissecting the molecular origins of opalescence and phase separation in mAb formulations and their relation to aggregation
Inna Brakti, Samuel Lenton, … Vito Foderà·bioRxiv·Aug 29, 2025
- Temperature and Excipient Mediated Modulation of Monoclonal Antibody Interactions Revealed by kD, Rheology, and Raman Spectroscopy
Olivia Noelle Eskens, Sabitoj Singh Virk, … Samiul Amin·mAbsPeer-reviewed·Jun 25, 2025
- In vitro and in vivo immunogenicity assessment of protein aggregate characteristics
C. Thorlaksen, H. S. Schultz, … M. Groenning·bioRxiv·Jul 6, 2022